• Prelude Therapeutics posted a first-quarter net loss of USD 10.4 million, narrowing from USD 32.1 million a year earlier, while revenue swung to USD 4.58 million from no revenue.
• R&D expense fell to USD 13.6 million from USD 28.8 million, due to lower costs tied to SMARCA2 clinical trials paused in 2025.
• Cash, cash equivalents, restricted cash and marketable securities totaled USD 84.8 million as of March 31, 2026; a subsequent underwritten offering raised gross proceeds of about USD 90 million.
• Cash runway expected into second quarter of 2028, while enrollment began in a Phase 1 study of PRT12396 in polycythemia vera and myelofibrosis patients.
• IND filing for KAT6A degrader PRT13722 expected by mid-2026, with Phase 1 initiation in ER+ breast cancer anticipated in second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120701PRIMZONEFULLFEED9717675) on May 12, 2026, and is solely responsible for the information contained therein.